**INCLUSION/EXCLUSION CRITERIA FOR EDOXABAN**

**Inclusion Criteria:**

* Pt is over 18
* Pt is currently registered as AF patient and takes medication: Apixaban, Rivaroxaban, Dabigatran

**Exclusion Criteria:**

* Patients with active malignancy/chemotherapy
* Current body weight >120Kg or BMI >40Kg/m2
* Creatinine Clearance (CrCl) 30 - 49mls/min and on apixaban 5mg BD
* Hx of GI bleeding and stable on current DOAC and PPi
* Patients with high risk of gastrointestinal (GI) bleed e.g., if on concomitant medication that increases the risk of GI bleeding/gastritis/ oesophagitis and stable on current DOAC and PPI
* Changed from alternative DOAC in past due to intolerance/treatment failure
* Patients prescribed a DOAC for another documented indication other than solely for AF stroke prevention
* Patients on two anticoagulants including DOACs, warfarin and low molecular weight heparins Valvular AF i.e., moderate to severe mitral valve stenosis
* Patients with prosthetic mechanical heart valves
* Severe renal impairment; most recent Creatinine Clearance <15ml/min (dabigatran
* CrCl<30ml/min) or a declining trend in renal function during the last 12 months or most

recent 3 values

* Severe hepatic impairment or hepatic impairment including:
* Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
* including cirrhotic patients with Child Pugh B and C
* Those patients where the clinical lead’s assessment advises the patient will not cope with

change to medicines

* Antiphospholipid syndrome
* Pregnancy, breast feeding or planning pregnancy
* Non-adherence to DOAC regimen/ compliance issues
* Recent acute admission to hospital within 3 months, that may have had an impact on renal

function and baseline bloods

* Patients with thrombocytopenia